Eye or eyelid involvement in atopic dermatitis is relatively uncommon. However, the frequency and severity of corneal complications may accompany atopic keratoconjunctivitis and lead to vision loss. In all but the mildest cases of AKC, treatment typically consists of corticosteroids; calcineurin inhibitors may be added in more severe cases.
Instructional handouts help caregivers stick to complicated treatment plans for pediatric AD patients. Historically effective AD treatments are being augmented with new phosphodiesterase inhibitors and biologics. Gentler approaches such as massage, light therapy, and melatonin may also be of value for children with AD.
Drugs to treat atopic dermatitis are at the top of the FDA’s dermatology list. Biologics and PDE4 inhibitors show promise in the treatment of AD. Approval is still needed for the use of biologics to treat AD in pediatric patients.
Emerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
Stepwise introduction of egg (starting with a low dose, which is then increased), along with aggressive treatment of atopic dermatitis (AD), is a safe and effective way to prevent hen’s egg allergy in high-risk infants, a study in Japan showed.
New recommendations for infant exposure to peanuts to prevent peanut allergy address something many pediatricians have long suspected: Early exposure to peanuts, even in infants that have eczema, could prevent development of peanut allergy.